Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus
- PMID: 8363756
- DOI: 10.1097/00002030-199306000-00005
Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus
Abstract
Objective: To investigate the role of the anti-cellular immune response in the protection of rhesus macaques against infection with the simian immunodeficiency virus SIVmac. To determine the biological differences between SIV challenge stocks grown either on human T-cell lines or on monkey peripheral blood mononuclear cells (MPBMC).
Design: A protective SIVmac split vaccine was administered to rhesus macaques and their anti-, B- and T-cell response monitored. Vaccinees and controls were challenged with SIVmac grown either on human or on monkey cells. The in vivo replication rate of, and the immune response to, the two viruses was compared.
Methods: Five rhesus macaques were immunized with a total of 2 mg each of purified SIVmac251/32H grown on the human C8166 T-cell line. The antibody and proliferative T-cell responses were evaluated by enzyme-linked immunosorbent assay and T-cell proliferation assay, respectively. Four protected animals and four controls were reboosted and challenged with MPBMC-grown SIVmac251 (SIVmac251/MPBMC). Cell-free virus load was determined by titration of plasma for SIV infectivity on C8166 cells and antigen with a core antigen capture assay.
Results: Protection from virus challenge with C8166-grown SIVmac251/32H or SIVmac251/MPBMC did not correlate with anti-cellular antibodies or proliferative T-cell reactivities. Control animals infected with SIVmac251/MPBMC showed high persistent antigenaemia and high plasma virus titres. Both were absent in controls infected with complement C8166-grown SIVmac251/32H. Whereas the latter always seroconverted against the full panel of viral polypeptides, SIVmac251/MPBMC-infected animals showed a drastically decreased antibody response.
Conclusions: Neither the antibody nor the proliferative T-cell response to SIVmac correlates with protection from virus challenge. In contrast to SIVmac251/32H grown on C8166 cells, the MPBMC-grown challenge virus SIVmac251 appears to belong to the 'rapid-high' phenotype, possibly explaining the lack of protection against this SIV.
Similar articles
-
Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.J Virol. 2002 Nov;76(22):11365-78. doi: 10.1128/jvi.76.22.11365-11378.2002. J Virol. 2002. PMID: 12388697 Free PMC article.
-
Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S27-32. AIDS Res Hum Retroviruses. 1994. PMID: 7865316
-
Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge.J Gen Virol. 1995 Jun;76 ( Pt 6):1307-15. doi: 10.1099/0022-1317-76-6-1307. J Gen Virol. 1995. PMID: 7782761
-
Simian immunodeficiency virus-specific cytotoxic T lymphocytes in rhesus monkeys: characterization and vaccine induction.Semin Immunol. 1993 Jun;5(3):215-23. doi: 10.1006/smim.1993.1025. Semin Immunol. 1993. PMID: 8394161 Review.
-
The SIVmac specific cytotoxic T lymphocyte response in the acutely infected rhesus monkey.Curr Top Microbiol Immunol. 1994;188:175-84. doi: 10.1007/978-3-642-78536-8_10. Curr Top Microbiol Immunol. 1994. PMID: 7924426 Review. No abstract available.
Cited by
-
Increased BST2 expression during simian immunodeficiency virus infection is not a determinant of disease progression in rhesus monkeys.Retrovirology. 2015 Nov 10;12:92. doi: 10.1186/s12977-015-0219-8. Retrovirology. 2015. PMID: 26554913 Free PMC article.
-
Current progress in the development of a prophylactic vaccine for HIV-1.Drug Des Devel Ther. 2010 Dec 22;5:9-26. doi: 10.2147/DDDT.S6959. Drug Des Devel Ther. 2010. PMID: 21267356 Free PMC article. Review.
-
Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.J Virol. 1997 Dec;71(12):9475-81. doi: 10.1128/JVI.71.12.9475-9481.1997. J Virol. 1997. PMID: 9371609 Free PMC article.
-
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.J Virol. 1996 Jun;70(6):3724-33. doi: 10.1128/JVI.70.6.3724-3733.1996. J Virol. 1996. PMID: 8648707 Free PMC article.
-
Protective role of the virus-specific immune response for development of severe neurologic signs in simian immunodeficiency virus-infected macaques.J Virol. 1998 Dec;72(12):9940-7. doi: 10.1128/JVI.72.12.9940-9947.1998. J Virol. 1998. PMID: 9811731 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources